Pancreatic Cancer Research

ResearcherWayne State UniversityActive in the last 2 years

Bin Bao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-9312-5096; OpenAlex author ID A5101427104, A5102482537. Sources: OpenAlex.

Their work

Papers
23
Trials
0
Grants
0
Labs led
0
Collaborators
28
Papers, trials and grants by year

2011: 7 papers · 2012: 5 papers · 2013: 3 papers · 2014: 3 papers · 2015: none · 2016: none · 2017: none · 2018: 2 papers · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 2 papers · 2026: 1 paper

Papers 23

  1. XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2026.218804↗
  2. Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcinoma Co-author DOI 10.1101/2025.11.21.689857↗
  3. PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic Cancer Co-author DOI 10.64898/2025.12.06.692635↗
  4. Retraction notice to "Increased Ras GTPase activity is regulated by miRNAs that can be attenuated by CDF treatment in pancreatic cancer cells" [Cancer Lett. 31… Co-author DOI 10.1016/j.canlet.2017.11.030↗
  5. Retraction notice to "Notch-1 induces Epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells". Co-author DOI 10.1016/j.canlet.2018.03.020↗
  6. Deregulation of miR-146a expression in a mouse model of pancreatic cancer affecting EGFR signaling. Co-author DOI 10.1016/j.canlet.2014.05.013↗
  7. Pancreatic cancer stem-like cells display aggressive behavior mediated via activation of FoxQ1. Co-author DOI 10.1074/jbc.m113.532887↗
  8. Differentially expressed miRNAs in cancer-stem-like cells: markers for tumor cell aggressiveness of pancreatic cancer. Co-author DOI 10.1089/scd.2013.0551↗
  9. Activated K-Ras and INK4a/Arf deficiency promote aggressiveness of pancreatic cancer by induction of EMT consistent with cancer stem cell phenotype. Co-author DOI 10.1002/jcp.24162↗
  10. Pancreatic cancer stem cells: emerging target for designing novel therapy. Co-author DOI 10.1016/j.canlet.2012.03.018↗
  11. Selective inhibitors of nuclear export block pancreatic cancer cell proliferation and reduce tumor growth in mice. Co-author DOI 10.1053/j.gastro.2012.10.036↗
  12. Inactivation of Ink4a/Arf leads to deregulated expression of miRNAs in K-Ras transgenic mouse model of pancreatic cancer. Co-author DOI 10.1002/jcp.24036↗
  13. RETRACTED: Increased Ras GTPase activity is regulated by miRNAs that can be attenuated by CDF treatment in pancreatic cancer cells. Co-author DOI 10.1016/j.canlet.2012.01.013↗
  14. Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Co-author DOI 10.1158/1940-6207.capr-11-0299↗
  15. Hypoxia-induced aggressiveness of pancreatic cancer cells is due to increased expression of VEGF, IL-6 and miR-21, which can be attenuated by CDF treatment. Co-author DOI 10.1371/journal.pone.0050165↗
  16. Genistein inhibits cell growth and induces apoptosis through up-regulation of miR-34a in pancreatic cancer cells. Co-author DOI 10.2174/138945012804545597↗
  17. Over-expression of FoxM1 leads to epithelial-mesenchymal transition and cancer stem cell phenotype in pancreatic cancer cells. Co-author DOI 10.1002/jcb.23150↗
  18. The complexities of obesity and diabetes with the development and progression of pancreatic cancer. Co-author DOI 10.1016/j.bbcan.2010.11.003↗
  19. Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. Co-author DOI 10.1016/j.canlet.2011.03.012↗
  20. Anti-tumor activity of a novel compound-CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer. Co-author DOI 10.1371/journal.pone.0017850↗
  21. Activated K-ras and INK4a/Arf deficiency cooperate during the development of pancreatic cancer by activation of Notch and NF-κB signaling pathways. Co-author DOI 10.1371/journal.pone.0020537↗
  22. Aberrant epigenetic grooming of miRNAs in pancreatic cancer: a systems biology perspective. Co-author DOI 10.2217/epi.11.97↗
  23. Network modeling of CDF treated pancreatic cancer cells reveals a novel c-myc-p73 dependent apoptotic mechanism. Co-author PMID 21904657↗

Closest collaborators

The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Asfar Sohail Azmi · 15 shared papers, 2011–2026 · strength 0.97
  2. Amro Aboukameel · 11 shared papers, 2011–2026 · strength 0.89
  3. Fazlul H. Sarkar · 20 shared papers, 2011–2018 · strength 0.75
  4. Ramzi M. Mohammad · 7 shared papers, 2011–2026 · strength 0.69
  5. Shadan S. Ali · 16 shared papers, 2011–2018 · strength 0.61
  6. Sahar F. Bannoura · 3 shared papers, 2025–2026 · strength 0.55
  7. Md. Hafiz Uddin · 3 shared papers, 2025–2026 · strength 0.55
  8. Boris Pasche · 3 shared papers, 2025–2026 · strength 0.55
  9. Mohammed Najeeb Al Hallak · 3 shared papers, 2025–2026 · strength 0.55
  10. Husain Yar Khan · 3 shared papers, 2025–2026 · strength 0.55
  11. Muhammad Wasif Saif · 3 shared papers, 2025–2026 · strength 0.55
  12. Bassel F. El‐Rayes · 3 shared papers, 2025–2026 · strength 0.55
  13. Sanjeev Banerjee · 15 shared papers, 2011–2018 · strength 0.51
  14. Philip A. Philip · 8 shared papers, 2011–2025 · strength 0.47
  15. P. A. Philip · 2 shared papers, 2025–2026 · strength 0.37
  16. Eliza Wright Beal · 2 shared papers, 2025–2026 · strength 0.37
  17. Anthony Frank Shields · 2 shared papers, 2025–2026 · strength 0.37
  18. Azeddine Atfi · 2 shared papers, 2025–2026 · strength 0.37
  19. Yiwei Li · 9 shared papers, 2011–2018 · strength 0.33
  20. Subhash Padhyé · 5 shared papers, 2011–2018 · strength 0.21
  21. Zhiwei Peter Wang · 5 shared papers, 2011–2018 · strength 0.19
  22. Lucio Miele · 5 shared papers, 2011–2018 · strength 0.18
  23. Steve H. Kim · 1 shared paper, 2025 · strength 0.17
  24. Murray Korc · 3 shared papers, 2011–2013 · strength 0.09
  25. Zhiwei Wang · 2 shared papers, 2011–2012 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.